An announcement from Sonnet BioTherapeutics Holdings ( (SONN) ) is now available.
Sonnet BioTherapeutics has successfully finished enrolling participants for its Phase 1 SB101 clinical trial of SON-1010, targeting advanced solid tumors, with topline data expected in Q4 2024. SON-1010, leveraging the company’s proprietary FHAB® platform, aims to enhance the drug’s half-life and tumor targeting by binding to native albumin in the serum. The study, which has reported no significant adverse effects, is designed to determine the maximum tolerated dose of SON-1010 and has shown promising safety and tolerability results, including controlled cytokine response and no instances of cytokine release syndrome, signaling a potential breakthrough in turning ‘cold’ tumors ‘hot’.
For detailed information about SONN stock, go to TipRanks’ Stock Analysis page.
